CERo Therapeutics (NASDAQ:CERO) Downgraded to “Hold” Rating by D Boral Capital

D Boral Capital downgraded shares of CERo Therapeutics (NASDAQ:CERO) from a strong-buy rating to a hold rating in a research note published on Tuesday morning,Zacks.com reports.

A number of other research analysts have also recently commented on CERO. Weiss Ratings restated a “sell (e+)” rating on shares of CERo Therapeutics in a research note on Wednesday, October 8th. Maxim Group downgraded shares of CERo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Finally, D. Boral Capital reiterated a “hold” rating on shares of CERo Therapeutics in a report on Tuesday. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $45.00.

CERo Therapeutics Stock Performance

NASDAQ CERO opened at $0.06 on Tuesday. The firm has a market capitalization of $72,300.00, a price-to-earnings ratio of 0.00 and a beta of 0.30. CERo Therapeutics has a one year low of $0.05 and a one year high of $572.00. The company’s 50 day moving average price is $2.92 and its 200 day moving average price is $6.97.

CERo Therapeutics (NASDAQ:CERO) last released its quarterly earnings data on Friday, August 22nd. The company reported ($61.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($70.23) by $8.52.

Hedge Funds Weigh In On CERo Therapeutics

An institutional investor recently bought a new stake in CERo Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 312,000 shares of the company’s stock, valued at approximately $228,000. Armistice Capital LLC owned approximately 5.80% of CERo Therapeutics as of its most recent SEC filing. 29.64% of the stock is owned by institutional investors.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.